Allopecia - Healing Genes


Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Biocellular-Cellular Regenerative Treatment Scarring Alopecia and Alopecia Areata (SAAA)

Biocellular Regenerative Therapy in Treating Scaring Alopecias and Alopecia Areata: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF)

Phase Not Applicable


Researchers in CA, MA, and MT are recruiting patients with allopecia to trial an investigatory regenerative cell therapy utilizing adipose-derived (from the fat tissue) stem cells and tissues in combination with plasma concentrate made from the blood. Depending on the portion of the study assigned, a combination of one or several of these will be infused intravenously, and hair growth assessment will be followed up for ~12 months.


  • Be 18 to 75 years of age
  • Have a biopsy proven diagnosis of a Scarring alopecia (SA) or Alopecia Areata (AA)
  • Willing to consent to fetal autopsy in the event of a fetal demise


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Liposuction recovery of adipose aspirate for cellular and tissue stromal vascular fraction, along with plasma draw and concentration. There will be lab prep time for these components.
  3. Infusion intravenously of the components (one or several, depending on the study group to which the patient is assigned).
  4. Follow up will continue with physical assessments ~12 months after treatment.


Trials will take place at Regeneris Medical in North Attleboro, MA (Map), and Regenevita in Stevensville, MT (Map), and at the Irvine Institute of Medicine & Cosmetic Surgery in Irvine, CA (Map).



Ryan Welter, MD, PhD  |  508.345.5492  |  [email protected]

Ken Williams, DO  |  1.949.333.2999  |  [email protected]



Regeneris Medical

Global Alliance for Regenerative Medicine


Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader